|
|
|
| home > ebr > Spring 2021 |
|
|
 PUBLICATIONS |
European Biopharmaceutical Review |
|
|
|
|
|
 |
| |
|
|
|
|
|
Autologous, Allogeneic CAR T, and the New Frontiers of CAR NK Immunotherapy Products
Claudia Benati, Giulia Mancini, Stanley Prince, Marian L McKee,
and Frederic Girard at Eurofins Biopharma Product Testing
Fighting cancer could be supported by the development and continued improvement in T cell and
NK cell immunotherapy. As this complex area of work continues to evolve, the chance to find the
next generation of cancer treatments improves
|
|
|
|
Droplet Digital PCR for
Safe and Effective CAR T
Cell Therapies
Mark White at Bio-Rad
ddPCR can quantify transgene copy numbers more precisely than standard qPCR
and reduce risk for patients, but how else can it support CAR T cell production?
|
|
|
|
A Look into Leukopaks
Stephanie Nickles Thielemann and Andrew Winner at Lonza discuss the future of immunology
and cell therapy, looking at how using cryopreserved leukopaks can alleviate several key
research challenges
|
|
|
|
|
|
Expediting Next-Generation
Vaccine Development Using
Advanced Analytical Methods
As Sartorius expands on its impressive portfolio, the company explores how the COVID-19
pandemic has brought to the fore novel analytical methods to ensure speed and efficacy
throughout the rollout proces
|
|
|
|
Beyond Cold
Dr Alex Esmon at Thermo Fisher Scientific
Vaccines have fundamentally changed with innovative mRNA and viral vector technologies driving
their development. These new types of vaccines have unique cold storage requirements, which
standard refrigerators and freezers cannot meet. Instead, ultra-low temperature freezers are
needed to support vaccine storage
|
|
|
|
A Challenge of Pandemic Proportions
Dr Steve Cutler, CEO of ICON, reveals what it was like running one of the biggest vaccine trials
ever, and how it proved the value of partnership, and the key role of technology
|
|
|
|
|
|
Endotoxins – The
Unwanted Contaminants
in Biomaterials for
Regenerative Medicines
Elien Gevaert, Principle Scientist at Rousselot Biomedical, talks about these disrupters of in vitroand in vivo cell growth and how they can stifle research and delay lab to clinic translation
|
|
|
|
The Green Shoots of
Tomorrow’s Cell Therapies
Thomas Marx and Dr Boris Greber at RheinCell Therapeutics GmbH
The potential of induced pluripotent stem cells as starting materials for novel advanced
therapies, and the importance of innovation for the next generation
|
|
|
|
Culture Shock: The Impact
of Cell Culture-Based
Technology in a New World
Anastassia Tselikova, Justin Field, and
Omid Taghavian at FUJIFILM Irvine Scientific
Biotechnology has changed the scope of medicine in recent years. The potential of cell therapy is
infinite, and the industry is now realising that the horizon of possibility is theirs for the taking
|
|
|
|
Defining Cell Culture
Conditions to Drive Cell
Identity and Scalability
in Cell Therapy
Dr Aida Moreno-Moral and
Dr David Anderson at Mogrify
Using epigenetically predicted factors to mimic in vivo microenvironments and systematically
define in vitro culture conditions for optimal cell maintenance and differentiation
|
|
|
|
|
Optimising Technical Transfers
Vladas Algirdas Bumelis, Prof., André Markmann, PhD, and Dominic Chow, PhD, at Northway Biotech offer insight into the challenges of tech transfers, and how the process can be improved
|
|
|
|
The Next Big Thing in
Sequencing Is Likely to
Be Very Small
Paul Lomax at SPT Labtech
Next-generation sequencing is the heartbeat of modern genomics. The growth in the variety of
techniques and applications is matched by the year-on-year cost reductions with the advent
of the $100 genome now a matter of when rather than if
|
|
|
|
Presenting the
Fluidity One-W Serum
At Fluidic Analytics, we have developed a new instrument that enables comprehensive profiling
of protein-protein interactions, such as the antibody response to SARS-CoV-2, based on affinity – a
crucial characteristic of protein interactions that traditional tests cannot easily quantify
|
|
|
|
Building Connective
Tissue into Fine Chemical
Markets
Gilles Cottier, Ed Roullard, Varun Vijay
Rao, and Keith Wilkinson at Aceto
For a pharmaceutical company, choosing suppliers and partners is an extremely important
decision, and there are three key considerations that should be kept in mind when making
this choice
|
|
|
|
Streamlining Biotech R&D
Dr Lukas Neutsch at ZHAW
What are the technical and conceptual requirements for taking research-oriented labs and
production facilities to the cutting-edge standard of connectivity and holistic data exploitation?
|
|
|
|
COVID-19 Highlights the Value of Drug Repurposing and Why We Should Continue
Pete Buckman at Medidata
What can be learned from the whirlwind of repurposed drug trials for COVID-19,
and how can repurposing help in future?
|
|
|
|
|
|
|
|
|
 |
|
|
 |
News and Press Releases |
 |
Nemera wins Pharmapack Award in Connected Devices and Wearables category with its body injector platform Symbioze
Symbioze, the smart, high volume and sustainable on-body injector
platform developed by Nemera, wins the ‘Connected Devices and Wearables’
Award at Pharmapack 2021
On October 12th,
during the Pharmapack Awards Ceremony, a team of industry experts
awarded Symbioze, Nemera’s large-volume on-body injector, with the
Pharmapack Award in the “Connected Devices and Wearables” category.
More info >> |
|
 |
White Papers |
 |
|
R&D to Product: How to Reduce Costly Scale-Up Problems
Natoli Engineering Company, Inc.
When scaling a new drug formulation from the development side of R&D into manufacturing, there is often a reality check with respect to process scaleup and performance of the formulation at production levels. Problems with capping/lamination and sticking/ picking are often first realized when a formulation is introduced to a level of compression required to supply market demand.
More info >> |
|
|
.jpg)
